-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previously, the 13-province alliance led by Guangdong for the renewal of the national procurement bid, a total of 233 enterprises signed up, involving 690 varieties, the results of the selection showed that 132 enterprises of 314 varieties were selected, and the selection rate was 70.
45%; the average price dropped by 27.
5%
.
This time, it was Henan’s turn to take the lead, and it was still the 13-province alliance.
However, Guangdong, Gansu, and Jiangxi were not covered by the provinces.
Instead, they were replaced by Chongqing, Hubei, and Inner Mongolia.
Other provinces and cities remained unchanged
.
From the perspective of procurement scope, the procurement scope of the 13-province alliance led by Guangdong includes a total of 45 varieties in the first and third batches of domestic production, while the procurement scope led by Henan this time is the second and fourth batches of national procurement, a total of 33 varieties, which are worth mentioning.
What's more, Henan Province will also carry out the first batch of centralized procurement of 18 varieties and the reported volume of cefasamine by Guangdong Alliance
.
Judging from the list, the second and fourth batches of domestically selected varieties include amoxicillin capsules, glimepiride tablets, esomeprazole enteric-coated capsules, ibuprofen tablets, and duloxetine hydrochloride enteric-coated capsules , Enpagliflozin tablets and other commonly used drug varieties and large clinical varieties, the companies involved include Qilu Pharmaceutical, Kelun, Renfu Pharmaceutical, Chia Tai Tianqing, Haisco, Huahai Pharmaceutical,
etc.
The first batch of 18 varieties collected in Henan Province includes ozagrel sodium, piracetam, compound glycyrrhizin, puerarin, gastrodin, and production of statin, involving Shuanglu Pharmaceutical, Sinopharm, Huaren Pharmaceutical, Baiyunshan, Lepu Pharmaceutical, China Resources Shuanghe, Yuekang Pharmaceutical and other enterprises
.
Guangdong Alliance's oral normal-release dosage form and cefasamine sustained-release controlled-release dosage form are also on the list.
The manufacturers are Kelun Pharmaceuticals and Hansoh Pharmaceuticals
.
The data show that cephalexin is a first-generation cephalosporin, which belongs to β-lactams
.
The mechanism of action of cephalexin is to inhibit the synthesis of the cell wall of bacterial dividing cells by binding to one or more penicillin-binding proteins (PBPs) of bacteria (cefalexin mainly binds to PBP-3), thereby exerting an antibacterial effect
.
It is clinically suitable for acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory tract infections, otitis media, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria.
.
The first-generation cephalosporins are recommended by the "Guidelines for the Clinical Application of Antibacterial Drugs" (2015 edition) as the appropriate or optional drugs for acute bacterial respiratory tract infections, urinary tract infections, and skin and soft tissue infections, and are approved by the "2018 NICE/PHE Guidelines: Antimicrobial Prescribing for Catheter-Associated Urinary Tract Infections” is recommended as first-line medication
.
The dosage forms of cephalexin currently listed in China include tablets, capsules, granules and other dosage forms
.
Among them, cephalexin tablets have been included in the 2020 National Class A Medical Insurance Catalogue
.
According to the data of Minet.
com, there are 164 approval documents for cephalexin tablets and 111 manufacturers, including 105 manufacturers of 0.
25g
.
In 2020, the domestic sales of cephalexin tablets is about 90 million yuan
.
According to the schedule, Henan medical institutions should fill in the demand for the next year from April 18, 2022 to April 26, 2022 (July 1, 2022 to June 30, 2023)
.
At the same time, the Henan Provincial Medical Insurance Bureau requires that all medical institutions should adhere to seeking truth from facts, and reasonably fill in the pre-purchased volume of medicines based on the unit's agreed procurement volume and the actual use of the previous procurement cycle
.
In principle, the pre-purchased amount shall not be less than the actual consumption of the unit in the previous procurement cycle.
If the increase or decrease exceeds 20%, an explanation shall be made.
For medical institutions that deliberately under-report or do not report the amount, the medical insurance departments at all levels shall issue a letter.
Ask for an appointment
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
45%; the average price dropped by 27.
5%
.
This time, it was Henan’s turn to take the lead, and it was still the 13-province alliance.
However, Guangdong, Gansu, and Jiangxi were not covered by the provinces.
Instead, they were replaced by Chongqing, Hubei, and Inner Mongolia.
Other provinces and cities remained unchanged
.
From the perspective of procurement scope, the procurement scope of the 13-province alliance led by Guangdong includes a total of 45 varieties in the first and third batches of domestic production, while the procurement scope led by Henan this time is the second and fourth batches of national procurement, a total of 33 varieties, which are worth mentioning.
What's more, Henan Province will also carry out the first batch of centralized procurement of 18 varieties and the reported volume of cefasamine by Guangdong Alliance
.
Judging from the list, the second and fourth batches of domestically selected varieties include amoxicillin capsules, glimepiride tablets, esomeprazole enteric-coated capsules, ibuprofen tablets, and duloxetine hydrochloride enteric-coated capsules , Enpagliflozin tablets and other commonly used drug varieties and large clinical varieties, the companies involved include Qilu Pharmaceutical, Kelun, Renfu Pharmaceutical, Chia Tai Tianqing, Haisco, Huahai Pharmaceutical,
etc.
The first batch of 18 varieties collected in Henan Province includes ozagrel sodium, piracetam, compound glycyrrhizin, puerarin, gastrodin, and production of statin, involving Shuanglu Pharmaceutical, Sinopharm, Huaren Pharmaceutical, Baiyunshan, Lepu Pharmaceutical, China Resources Shuanghe, Yuekang Pharmaceutical and other enterprises
.
Guangdong Alliance's oral normal-release dosage form and cefasamine sustained-release controlled-release dosage form are also on the list.
The manufacturers are Kelun Pharmaceuticals and Hansoh Pharmaceuticals
.
The data show that cephalexin is a first-generation cephalosporin, which belongs to β-lactams
.
The mechanism of action of cephalexin is to inhibit the synthesis of the cell wall of bacterial dividing cells by binding to one or more penicillin-binding proteins (PBPs) of bacteria (cefalexin mainly binds to PBP-3), thereby exerting an antibacterial effect
.
It is clinically suitable for acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory tract infections, otitis media, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria.
.
The first-generation cephalosporins are recommended by the "Guidelines for the Clinical Application of Antibacterial Drugs" (2015 edition) as the appropriate or optional drugs for acute bacterial respiratory tract infections, urinary tract infections, and skin and soft tissue infections, and are approved by the "2018 NICE/PHE Guidelines: Antimicrobial Prescribing for Catheter-Associated Urinary Tract Infections” is recommended as first-line medication
.
The dosage forms of cephalexin currently listed in China include tablets, capsules, granules and other dosage forms
.
Among them, cephalexin tablets have been included in the 2020 National Class A Medical Insurance Catalogue
.
According to the data of Minet.
com, there are 164 approval documents for cephalexin tablets and 111 manufacturers, including 105 manufacturers of 0.
25g
.
In 2020, the domestic sales of cephalexin tablets is about 90 million yuan
.
According to the schedule, Henan medical institutions should fill in the demand for the next year from April 18, 2022 to April 26, 2022 (July 1, 2022 to June 30, 2023)
.
At the same time, the Henan Provincial Medical Insurance Bureau requires that all medical institutions should adhere to seeking truth from facts, and reasonably fill in the pre-purchased volume of medicines based on the unit's agreed procurement volume and the actual use of the previous procurement cycle
.
In principle, the pre-purchased amount shall not be less than the actual consumption of the unit in the previous procurement cycle.
If the increase or decrease exceeds 20%, an explanation shall be made.
For medical institutions that deliberately under-report or do not report the amount, the medical insurance departments at all levels shall issue a letter.
Ask for an appointment
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
